Companies › Zura Bio
1 active drug program in 2 registered trials: 2 Phase 2; Immunology, Infectious disease; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tibulizumab (ZB-106) Tumor necrosis factor ligand superfamily member 13B inhibitor; Interleukin 17A inhibitor | TNFSF13B, IL17A | Phase 2 | Hidradenitis Suppurativa (HS); Systemic Sclerosis (SSc) | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06993610 | Tibulizumab (ZB-106) | Phase 2 | Hidradenitis Suppurativa (HS) | Infectious disease | Apr 2027 |
| NCT06843239 | Tibulizumab (ZB-106) | Phase 2 | Systemic Sclerosis (SSc) | Immunology | May 2027 |
Cash of $188m on 2026-09-30; operating cash outflow about $0m a year; runway about 28288 months at that burn, to Mar 4381; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Celltrion GSK Vera Therapeutics Luminary Therapeutics Novartis MoonLake Immunotherapeutics Suzhou Suncadia Biopharmaceuticals Biocad UCB Biopharma SRL Eli Lilly
MoonLake Immunotherapeutics Q32 Bio AnaptysBio RAPT Therapeutics, Inc., a member of the GSK plc group of companies Trellis Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.